MedTrace Logo

Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents

NCT01574235 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2114

Last updated 2015-07-28

No results posted yet for this study

Summary

The main aim of the study is to assess the safety of Nivestim® treatment in patients treated with neutropenia-inducing chemotherapy for a malignant disease, solid tumor or a malignant hemopathy.

Conditions

  • Solid Tumors
  • Malignant Hemopathy
  • Chemotherapy-induced Febrile Neutropenia (FN)

Interventions

BIOLOGICAL

Nivestim®

Sponsors & Collaborators

  • Hospira, now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01574235 on ClinicalTrials.gov